Market capitalization | $69.18m |
Enterprise Value | $31.34m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.80 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-22.58m |
Free Cash Flow (TTM) Free Cash Flow | $-16.67m |
Cash position | $39.07m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Hancock Jaffe Laboratories, Inc.:
1 Analyst has issued a forecast Hancock Jaffe Laboratories, Inc.:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.55 -0.55 |
2%
2%
|
|
EBITDA | -22 -22 |
14%
14%
|
EBIT (Operating Income) EBIT | -23 -23 |
14%
14%
|
Net Profit | -21 -21 |
18%
18%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include The Bioprosthetic Heart Valve, The CoreoGraft, and The Venous Valve. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.
Head office | United States |
CEO | Robert Berman |
Employees | 31 |
Founded | 1999 |
Website | www.envveno.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.